GlassScriptPhysician profile
Christopher Nicholas Riggan
NPI 1174171383
$1,004.66
in general payments reported to CMS, 2019-2025
18 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $572 · 2022: $12.78 · 2024: $79.11 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $201.45 | 2021-2025 | Rexulti |
| Abbvie INC. | $129.72 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $99.97 | 2021-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $90.63 | 2021 | |
| Collegium Pharmaceutical, INC. | $74.77 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $65.53 | 2024 | |
| Tris Pharma INC | $57.06 | 2024-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $53.32 | 2021 | |
| Jazz Pharmaceuticals INC. | $50.77 | 2021 | |
| Corium, LLC | $35.70 | 2025 | Azstarys |
| Lundbeck LLC | $26.05 | 2021 | |
| Supernus Pharmaceuticals, INC. | $23.88 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.02 | 2025 | Trintellix |
| Tms Neurohealth Centers INC. | $18.50 | 2025 | Tms Neurohealth Centers INC. |
| Axsome Therapeutics, INC. | $17.17 | 2025 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $16.99 | 2025 | Spravato |
| Neurocrine Biosciences, INC. | $12.35 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Riggan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.